Is VRTX a good stock to buy?
We came across a bullish thesis on Vertex Pharmaceuticals Incorporated on r/investing_discussion by Variant_Invest
In this article, we will summarize the bulls’ thesis on VRTX. Vertex Pharmaceuticals Incorporated’s share was trading at $445.77 as of June 9th. VRTX’s trailing and forward P/E were 26.46 and 23.47 respectively according to Yahoo Finance.
Pressmaster/ Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. VRTX is being mispriced by the market, which continues to frame it narrowly as a high-quality but mature cystic fibrosis company, despite it evolving into a broader, pipeline-driven biotech with multiple late-stage growth drivers. The core cash engine remains its cystic fibrosis franchise, which targets the full spectrum of cystic fibrosis disease caused by CFTR gene mutations. 15 AI Stocks That Are Quietly Making Investors Rich Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential This franchise, led by Trikafta, effectively treats the underlying biology of entire cystic fibrosis rather than just managing symptoms, resulting in near-monopoly positioning, exceptional durability, and long-duration recurring revenues as patients remain on therapy for life.